In vivo 19F MRI and 19F MRS of 19F- labelled boronophenylalanine-fructose complex on a C6 rat glioma model to optimize boron neutron capture therapy (BNCT)

Paola Porcari, Silvia Capuani, Emanuela D'Amore, Mario Lecce, Angela La Bella, Fabrizio Fasano, Renzo Campanella, Luisa Maria Migneco, Francesco Saverio Pastore, Bruno Maraviglia

Research output: Contribution to journalArticlepeer-review

Abstract

Boron neutron capture therapy (BNCT) is a promising binary modality used to treat malignant brain gliomas. To optimize BNCT effectiveness a non-invasive method is needed to monitor the spatial distribution of BNCT carriers in order to estimate the optimal timing for neutron irradiation. In this study, in vivo spatial distribution mapping and pharmacokinetics evaluation of the 19F-labelled boronophenylalanine (BPA) were performed using 19F magnetic resonance imaging (19F MRI) and 19F magnetic resonance spectroscopy (19F MRS). Characteristic uptake of 19F-BPA in C6 glioma showed a maximum at 2.5 h after compound infusion as confirmed by both 19F images and 19F spectra acquired on blood samples collected at different times after infusion. This study shows the ability of 19F MRI to selectively map the bio-distribution of 19F-BPA in a C6 rat glioma model, as well as providing a useful method to perform pharmacokinetics of BNCT carriers.

Original languageEnglish
Pages (from-to)6979-6989
Number of pages11
JournalPhysics in Medicine and Biology
Volume53
Issue number23
DOIs
Publication statusPublished - Dec 7 2008

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'In vivo 19F MRI and 19F MRS of 19F- labelled boronophenylalanine-fructose complex on a C6 rat glioma model to optimize boron neutron capture therapy (BNCT)'. Together they form a unique fingerprint.

Cite this